Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001641172-25-006421
Filing Date
2025-04-28
Accepted
2025-04-28 16:05:08
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 4886
  Complete submission text file 0001641172-25-006421.txt   6790
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Subject) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-88372 | Film No.: 25880222
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address ONE BOSTON PLACE SUITE 2600 BOSTON MA 02108
Business Address ONE BOSTON PLACE SUITE 2600 BOSTON MA 02108 617-904-9195
Opaleye Management Inc. (Filed by) CIK: 0001595855 (see all company filings)

EIN.: 205648796 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G/A